Switzerland – AfricaNewsAnalysis

Novartis launches ‘Novartis Access’, a portfolio of affordable medicines to treat chronic diseases in lower-income countries

29/09/2015 ANA 0

First-of-its-kind portfolio approach in healthcare industry, aiming to increase availability and affordability of 15 medicines against cardiovascular diseases, diabetes, respiratory illnesses and breast cancer Novartis portfolio to be offered to governments and non-governmental organizations in […]

Ebola: Merck, UNESCO and Cambridge University join hands to build Research Capacity in Africa with the aim to fight against Ebola

15/07/2015 ANA 0

Merck (http://www.merckgroup.com), the world’s oldest pharmaceutical and Chemical company in partnership with UNESCO , Cambridge University and University of Rome plan to conduct UNESCO-Merck Africa Research Summit – MARS which will be held on the […]

Novartis announces portfolio transformation, focusing company on leading businesses with innovation power and global scale: Pharmaceuticals, Eye Care and Generics

24/04/2014 ANA 0

Novartis announced today (April 22, 2012) that it has reached a definitive agreement with GlaxoSmithKline plc (GSK) to exchange certain assets, building global leadership in key segments and focusing the company’s portfolio. Under the agreement, Novartis […]

Novartis to request re-examination of serelaxin (RLX030) in acute heart failure (AHF) for conditional marketing authorization in EU

24/01/2014 ANA 0

Novartis announced today it will shortly submit a revised filing package, including new data analyses, for re-examination for conditional approval of RLX030 (serelaxin) for acute heart failure by the Committee for Medicinal Products for Human […]

Novartis reports positive opinion from CHMP for Xolair® in severe form of skin disease CSU, a debilitating form of hives and chronic itch

24/01/2014 ANA 0

Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the use of Xolair® (omalizumab) as an add-on therapy for […]

Novartis highlights research on investigational, personalized T cell therapy CTL019 in patients with forms of acute and chronic leukemia

08/12/2013 ANA 0

Novartis is highlighting new research from members of the faculty at the University of Pennsylvania’s Perelman School of Medicine (Penn) on the investigational chimeric antigen receptor (CAR) therapy, CTL019. Several studies being presented at the […]

Le « Novartis Africa Day » met en lumière les initiatives de l’entreprise pour étendre l’accès aux soins de santé

05/12/2013 ANA 0

Aujourd’hui, les cadres dirigeants de Novartis se réunissent à Bâle, en Suisse, à l’occasion du premier « Novartis Africa Day ». Ils passeront en revue le travail mené par l’entreprise en Afrique, notamment l’activité commerciale croissante, les […]

Novartis Africa Day unterstreicht die Bemühungen des Unternehmens für einen besseren Zugang zur Gesundheitsversorgung

05/12/2013 ANA 0

Heute treffen sich Führungsverantwortliche von Novartis in Basel, Schweiz, für den ersten Novartis Africa Day. Sie werden dort die innovative Arbeit des Unternehmens in Afrika prüfen, insbesondere die wachsenden kommerziellen Aktivitäten, neuartige Ansätze für einen […]

Novartis Africa Day highlights company’s efforts to expand access to healthcare

05/12/2013 ANA 0

Today, Novartis senior executives gather in Basel, Switzerland for the first-ever Novartis Africa Day, to review the company’s innovative work in Africa, including growing commercial activity, novel approaches to expand access to high-quality, affordable medicines, […]

Novartis Foundation launches new leprosy strategy at symposium on disease elimination

30/11/2013 ANA 0

Friday’s symposium of the Novartis Foundation for Sustainable Development (NFSD) convenes experts to discuss “What does it take to eliminate a disease?” Drawing lessons from previous successful disease control programs, the symposium speakers discuss innovative […]

1 2 3 »